Please assess the completion status of the following clinical trial:

Trial Title: Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meets protocol-specified criteria for qualification and contraception~* Willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related food, drink and medications~* Voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures~Exclusion Criteria:~* History or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters~* Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:~  1. the safety or well-being of the participant or study staff;~ 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);~ 3. the analysis of results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine 0.5 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
- Buprenorphine 0.25 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
- Buprenorphine 0.125 mg TID (Type: EXPERIMENTAL): Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo-matching buprenorphine sublingual spray TID for two days.

Based on this trial design, predict the completion outcome and termination type (if applicable).